Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles

Francisco Vega, Chung Che Chang, Leonard J. Medeiros, Mark M. Udden, Jeong Hee Cho, Ching Ching Lau, Chris J. Finch, Regis A. Vilchez, David McGregor, Jeffrey L. Jorgensen

Research output: Contribution to journalArticle

216 Citations (Scopus)

Abstract

Plasmablastic lymphoma is an aggressive neoplasm that shares many cytomorphologic and immunophenotypic features with plasmablastic plasma cell myeloma. However, plasmablastic lymphoma is listed in the World Health Organization (WHO) classification as a variant of diffuse large B-cell lymphoma. To characterize the relationship between plasmablastic lymphoma and plasmablastic plasma cell myeloma, we performed immunohistochemistry using a large panel of B-cell and plasma cell markers on nine cases of plasmablastic lymphoma and seven cases of plasmablastic plasma cell myeloma with and without HIV/AIDS. The expression profiles of the tumor suppressor genes p53, p16, and p27, and the presence of Epstein-Barr virus (EBV) and human herpes virus type 8 (HHV-8) were also analyzed. All cases of plasmablastic lymphoma and plasmablastic plasma cell myeloma were positive for MUM1/IRF4, CD138, and CD38, and negative for CD20, corresponding to a plasma cell immunophenotype. PAX-5 and BCL-6 were weakly positive in 2/9 and 1/5 plasmablastic lymphomas, and negative in all plasmablastic plasma cell myelomas. Three markers that are often aberrantly expressed in cases of plasma cell myelomas, CD56, CD4 and CD10, were positive in 5/9, 2/5, and 6/9 plasmablastic lymphomas, and in 3/7, 1/5, and 2/7 plasmablastic plasma cell myelomas. A high Ki-67 proliferation index, overexpression of p53, and loss of expression of p16 and p27 were present in both tumors. No evidence of HHV-8 infection was detected in either neoplasm. The only significant difference between plasmablastic lymphoma and plasma cell myeloma was the presence of EBV-encoded RNA, which was positive in all plasmablastic lymphoma cases tested and negative in all plasma cell myelomas. In conclusion, most cases of AIDS-related plasmablastic lymphoma have an immunophenotype and tumor suppressor gene expression profile virtually identical to plasmablastic plasma cell myeloma, and unlike diffuse large B-cell lymphoma. These results do not support the suggestion in the WHO classification that plasmablastic lymphoma is a variant of diffuse large B-cell lymphoma.

Original languageEnglish
Pages (from-to)806-815
Number of pages10
JournalModern Pathology
Volume18
Issue number6
DOIs
StatePublished - Jun 1 2005
Externally publishedYes

Fingerprint

Multiple Myeloma
Lymphoma, Large B-Cell, Diffuse
Plasma Cells
Tumor Suppressor Genes
Human Herpesvirus 4
Plasmablastic Lymphoma
AIDS-Related Lymphoma
Neoplasms
Virus Diseases
Transcriptome
Acquired Immunodeficiency Syndrome
B-Lymphocytes
Immunohistochemistry
HIV
RNA
Viruses

Keywords

  • AIDS-related lymphomas
  • EBV infection
  • Plasmablastic lymphoma
  • Plasmablastic plasma cell myeloma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. / Vega, Francisco; Chang, Chung Che; Medeiros, Leonard J.; Udden, Mark M.; Cho, Jeong Hee; Lau, Ching Ching; Finch, Chris J.; Vilchez, Regis A.; McGregor, David; Jorgensen, Jeffrey L.

In: Modern Pathology, Vol. 18, No. 6, 01.06.2005, p. 806-815.

Research output: Contribution to journalArticle

Vega, F, Chang, CC, Medeiros, LJ, Udden, MM, Cho, JH, Lau, CC, Finch, CJ, Vilchez, RA, McGregor, D & Jorgensen, JL 2005, 'Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles', Modern Pathology, vol. 18, no. 6, pp. 806-815. https://doi.org/10.1038/modpathol.3800355
Vega, Francisco ; Chang, Chung Che ; Medeiros, Leonard J. ; Udden, Mark M. ; Cho, Jeong Hee ; Lau, Ching Ching ; Finch, Chris J. ; Vilchez, Regis A. ; McGregor, David ; Jorgensen, Jeffrey L. / Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. In: Modern Pathology. 2005 ; Vol. 18, No. 6. pp. 806-815.
@article{110a8b93675148768dfcb55c52fc0238,
title = "Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles",
abstract = "Plasmablastic lymphoma is an aggressive neoplasm that shares many cytomorphologic and immunophenotypic features with plasmablastic plasma cell myeloma. However, plasmablastic lymphoma is listed in the World Health Organization (WHO) classification as a variant of diffuse large B-cell lymphoma. To characterize the relationship between plasmablastic lymphoma and plasmablastic plasma cell myeloma, we performed immunohistochemistry using a large panel of B-cell and plasma cell markers on nine cases of plasmablastic lymphoma and seven cases of plasmablastic plasma cell myeloma with and without HIV/AIDS. The expression profiles of the tumor suppressor genes p53, p16, and p27, and the presence of Epstein-Barr virus (EBV) and human herpes virus type 8 (HHV-8) were also analyzed. All cases of plasmablastic lymphoma and plasmablastic plasma cell myeloma were positive for MUM1/IRF4, CD138, and CD38, and negative for CD20, corresponding to a plasma cell immunophenotype. PAX-5 and BCL-6 were weakly positive in 2/9 and 1/5 plasmablastic lymphomas, and negative in all plasmablastic plasma cell myelomas. Three markers that are often aberrantly expressed in cases of plasma cell myelomas, CD56, CD4 and CD10, were positive in 5/9, 2/5, and 6/9 plasmablastic lymphomas, and in 3/7, 1/5, and 2/7 plasmablastic plasma cell myelomas. A high Ki-67 proliferation index, overexpression of p53, and loss of expression of p16 and p27 were present in both tumors. No evidence of HHV-8 infection was detected in either neoplasm. The only significant difference between plasmablastic lymphoma and plasma cell myeloma was the presence of EBV-encoded RNA, which was positive in all plasmablastic lymphoma cases tested and negative in all plasma cell myelomas. In conclusion, most cases of AIDS-related plasmablastic lymphoma have an immunophenotype and tumor suppressor gene expression profile virtually identical to plasmablastic plasma cell myeloma, and unlike diffuse large B-cell lymphoma. These results do not support the suggestion in the WHO classification that plasmablastic lymphoma is a variant of diffuse large B-cell lymphoma.",
keywords = "AIDS-related lymphomas, EBV infection, Plasmablastic lymphoma, Plasmablastic plasma cell myeloma",
author = "Francisco Vega and Chang, {Chung Che} and Medeiros, {Leonard J.} and Udden, {Mark M.} and Cho, {Jeong Hee} and Lau, {Ching Ching} and Finch, {Chris J.} and Vilchez, {Regis A.} and David McGregor and Jorgensen, {Jeffrey L.}",
year = "2005",
month = "6",
day = "1",
doi = "10.1038/modpathol.3800355",
language = "English",
volume = "18",
pages = "806--815",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles

AU - Vega, Francisco

AU - Chang, Chung Che

AU - Medeiros, Leonard J.

AU - Udden, Mark M.

AU - Cho, Jeong Hee

AU - Lau, Ching Ching

AU - Finch, Chris J.

AU - Vilchez, Regis A.

AU - McGregor, David

AU - Jorgensen, Jeffrey L.

PY - 2005/6/1

Y1 - 2005/6/1

N2 - Plasmablastic lymphoma is an aggressive neoplasm that shares many cytomorphologic and immunophenotypic features with plasmablastic plasma cell myeloma. However, plasmablastic lymphoma is listed in the World Health Organization (WHO) classification as a variant of diffuse large B-cell lymphoma. To characterize the relationship between plasmablastic lymphoma and plasmablastic plasma cell myeloma, we performed immunohistochemistry using a large panel of B-cell and plasma cell markers on nine cases of plasmablastic lymphoma and seven cases of plasmablastic plasma cell myeloma with and without HIV/AIDS. The expression profiles of the tumor suppressor genes p53, p16, and p27, and the presence of Epstein-Barr virus (EBV) and human herpes virus type 8 (HHV-8) were also analyzed. All cases of plasmablastic lymphoma and plasmablastic plasma cell myeloma were positive for MUM1/IRF4, CD138, and CD38, and negative for CD20, corresponding to a plasma cell immunophenotype. PAX-5 and BCL-6 were weakly positive in 2/9 and 1/5 plasmablastic lymphomas, and negative in all plasmablastic plasma cell myelomas. Three markers that are often aberrantly expressed in cases of plasma cell myelomas, CD56, CD4 and CD10, were positive in 5/9, 2/5, and 6/9 plasmablastic lymphomas, and in 3/7, 1/5, and 2/7 plasmablastic plasma cell myelomas. A high Ki-67 proliferation index, overexpression of p53, and loss of expression of p16 and p27 were present in both tumors. No evidence of HHV-8 infection was detected in either neoplasm. The only significant difference between plasmablastic lymphoma and plasma cell myeloma was the presence of EBV-encoded RNA, which was positive in all plasmablastic lymphoma cases tested and negative in all plasma cell myelomas. In conclusion, most cases of AIDS-related plasmablastic lymphoma have an immunophenotype and tumor suppressor gene expression profile virtually identical to plasmablastic plasma cell myeloma, and unlike diffuse large B-cell lymphoma. These results do not support the suggestion in the WHO classification that plasmablastic lymphoma is a variant of diffuse large B-cell lymphoma.

AB - Plasmablastic lymphoma is an aggressive neoplasm that shares many cytomorphologic and immunophenotypic features with plasmablastic plasma cell myeloma. However, plasmablastic lymphoma is listed in the World Health Organization (WHO) classification as a variant of diffuse large B-cell lymphoma. To characterize the relationship between plasmablastic lymphoma and plasmablastic plasma cell myeloma, we performed immunohistochemistry using a large panel of B-cell and plasma cell markers on nine cases of plasmablastic lymphoma and seven cases of plasmablastic plasma cell myeloma with and without HIV/AIDS. The expression profiles of the tumor suppressor genes p53, p16, and p27, and the presence of Epstein-Barr virus (EBV) and human herpes virus type 8 (HHV-8) were also analyzed. All cases of plasmablastic lymphoma and plasmablastic plasma cell myeloma were positive for MUM1/IRF4, CD138, and CD38, and negative for CD20, corresponding to a plasma cell immunophenotype. PAX-5 and BCL-6 were weakly positive in 2/9 and 1/5 plasmablastic lymphomas, and negative in all plasmablastic plasma cell myelomas. Three markers that are often aberrantly expressed in cases of plasma cell myelomas, CD56, CD4 and CD10, were positive in 5/9, 2/5, and 6/9 plasmablastic lymphomas, and in 3/7, 1/5, and 2/7 plasmablastic plasma cell myelomas. A high Ki-67 proliferation index, overexpression of p53, and loss of expression of p16 and p27 were present in both tumors. No evidence of HHV-8 infection was detected in either neoplasm. The only significant difference between plasmablastic lymphoma and plasma cell myeloma was the presence of EBV-encoded RNA, which was positive in all plasmablastic lymphoma cases tested and negative in all plasma cell myelomas. In conclusion, most cases of AIDS-related plasmablastic lymphoma have an immunophenotype and tumor suppressor gene expression profile virtually identical to plasmablastic plasma cell myeloma, and unlike diffuse large B-cell lymphoma. These results do not support the suggestion in the WHO classification that plasmablastic lymphoma is a variant of diffuse large B-cell lymphoma.

KW - AIDS-related lymphomas

KW - EBV infection

KW - Plasmablastic lymphoma

KW - Plasmablastic plasma cell myeloma

UR - http://www.scopus.com/inward/record.url?scp=20344381814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20344381814&partnerID=8YFLogxK

U2 - 10.1038/modpathol.3800355

DO - 10.1038/modpathol.3800355

M3 - Article

VL - 18

SP - 806

EP - 815

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 6

ER -